In vitro anti-angiogenic properties of LGD1069, a selective retinoid X-receptor agonist through down-regulating Runx2 expression on Human endothelial cells
2011

Effects of LGD1069 on Blood Vessel Formation in Cancer

publication 10 minutes Evidence: moderate

Author Information

Author(s): Fu Jianjiang, Wang Wei, Liu Yu-Hui, Lu Hong, Luo Yongming

Primary Institution: Jiangxi University of Traditional Chinese Medicine

Hypothesis

Does LGD1069 inhibit angiogenesis and metastasis in human endothelial cells?

Conclusion

LGD1069 may impair the ability of tumor cells to promote blood vessel formation and metastasis by suppressing Runx2 expression in human endothelial cells.

Supporting Evidence

  • LGD1069 inhibited the proliferation, adhesion, invasion, and migration of endothelial cells.
  • Runx2 expression was significantly suppressed during incubation with LGD1069.
  • LGD1069 decreased the expression of matrix metalloproteinases (MMP-2 and MMP-9) in endothelial cells.

Takeaway

LGD1069 is a medicine that helps stop cancer from spreading by blocking the growth of blood vessels that feed tumors.

Methodology

The study used human umbilical vein endothelial cells (HUVECs) and various assays to measure cell viability, migration, invasion, and gene expression.

Limitations

The study was conducted in vitro, which may not fully represent in vivo conditions.

Participant Demographics

Human umbilical vein endothelial cells were used, but specific demographics of donors were not detailed.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-11-227

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication